Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling Now On Demand | Presented by Technology Networks Watch Now Greater use of small molecule biomarkers in drug development is needed to transform efficiency and success rates, by driving deeper understanding of how non-genetic factors influence disease pathobiology and drug responsiveness. In… Continue reading Advances in Proteomics & Metabolomics 2022 Online Symposium
Dr. Jain also shares his background and what led to him to creating Sapient along with the company’s own next-generation mass spectrometry-based technology platform used for biomarker discovery at scale.
Now On Demand | Hosted by AAPS Watch Now While next-generation sequencing has been instrumental in advancing genomics-based precision medicine, the full potential of personalized therapy has yet to be realized at scale. DNA biomarkers help identify genetic variants associated with disease susceptibility and therapeutic response, but are largely static measures of heritability. This has… Continue reading What’s Next in Precision Medicine? Small Molecule Biomarkers to Personalize Disease Prediction, Diagnostics and Therapies
Sapient recently contributed a piece to Fierce Pharma discussing the new biological and disease insights that small molecule biomarkers can bring to improve drug development success – and how next-generation mass spectrometry is enabling their discovery on an entirely new scale. Excerpt: Dynamic organ physiology, inter-organ communication, host-disease interactions, and host-environment exposures are encoded in… Continue reading Fierce Pharma Feature: Small molecule biomarkers to align patients, disease, and therapy
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics with data analysis and chemical interpretation for the study. The research is part… Continue reading University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating that 56% of adults in the study… Continue reading Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19
Now On Demand | Hosted by AAPS Watch Now Genome-wide association studies (GWAS) have been transformative in elucidating the genetic landscape of human disease, defining hundreds of common and rare genetic variants that contribute to the development of disease. The challenge to date, however, lies in understanding the biological mechanisms that underlie these genetic associations… Continue reading Mapping the Missing Link: Bridging the Gap Between Human Genetics and Disease Biology Through Small Molecule Biomarker Discovery
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022—San Diego, CA—Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a new grant from the Bill & Melinda Gates Foundation to use its rapid liquid chromatography-mass spectrometry (rLC-MS)… Continue reading Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis
An individual’s phenotype is not dictated solely by their genetic variants. Environmental factors – where we live, what we eat, exposures over time – interact with genes and can influence disease risk. See how small molecule biomarkers can be used to assess these environmental exposures and their influence on genes, to provide a more complete… Continue reading Genomic + Small Molecule Biomarkers: for a More Complete Picture of Disease Risk
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one minute. These technologies are embedded within an integrated discovery pipeline… Continue reading Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022
